Candesartan prevents L-NAME-induced cardio-renal injury in spontaneously hypertensive rats beyond hypotensive effects

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue SUPPL. 1, 2001, Pages

  Casellas, Daniel ^a   Herizi, Abderraouf ^a   Artuso, Annie ^a   Mimran, Albert ^a   Jover, Bernard ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Arterial remodelling; Cardiac hypertrophy; Glomerular injury; Interstitial fibrosis; Vascular injury

Indexed keywords

EID: 0012607261     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/14703203010020011501     Document Type: Article

References (35)

1. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertens 1998;32:958-64.
2. Kashiwagi M, Shinozaki M, Hirakata H et al. Locally activated renin-angiotensin system associated with TGF-β1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000;11:616-24.
3. Verhagen AM, Braam B, Boer P, Gröne H-J, Koomans HA, Joles JA. Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentration. Kidney Int 1999;56:222-31.
4. Pollock DM, Polakoski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertens 1993;21:660-8.
5. Bouriquet N, Dupont M, Herizi A, Mimran A, Casellas D. Preglomerular sudanophilia in L-NAME hypertensive rats: involvement of endothelin. Hypertens 1996;27[part 1]:382-91.
6. Takase H, Moreau P, Küng CF, Nava E, Lüscher TF. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertens 1996;27:25-31.
7. Michel J-B, Xu Y, Blot S, Philippe M, Chatelier G. Improved survival in rats administered NG-nitro-L-arginine methyl ester due to converting-enzyme inhibition. J Cardiovasc Pharmacol 1996;28:142-8.
8. Casellas D, Benahmed S. Artuso A, Jover B. Candesartan and progression of preglomerular lesions in NG-nitro-L-arginine methyl ester hypertensive rats. J Am Soc Nephrol 1999;10:S230-S233.
9. Numaguchi K, Egashira K, Takemoto M et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertens 1995;26[part 1]:957-62.
10. Takemoto M, Egashira K, Usui M et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997;99:278-87.
11. Bosse HM, Böhm R, Resch S, Bachmann S. Parallel regulation of constitutive NO synthase and renin at JGA of rat kidney under various stimuli. Am J Physiol 1995;269:F793-F805.
12. Tomita H, Egashira K, Ohara Y et al. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertens 1998;32:273-9.
13. Ono H, Ono Y, Frohlich ED. Nitric oxide synthase inhibition in spontaneously hypertensive rats. Systemic, renal and glomerular hemodynamics. Hypertens 1995;26:249-55.
14. Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW. Glomerular dynamics and morphology of aged spontaneously hypertensive rats: effects of angiotensin-converting enzyme inhibitor. Hypertens 1995;25:207-13.
15. Frohlich ED. Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertens 1997;29[part 2]:188-93.
16. Casellas D, Bouriquet N, Artuso A. Nitric oxide and preglomerular vascular lesions in Lyon spontaneously hypertensive rats.Acta Physiol Scand 2000;168:133-8.
17. Ono H, Ono Y, Frohlich ED. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertens 1996;27:176-83.
18. Qiu C, Bruneval P, Roeckel A, Heudes D, Duong Van Huyen J-P, Roux S. Mibefradil prevents L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. J Hypertens 1999;17:1489-95.
19. Casellas D, Dupont M, Kaskel FJ, Inagami T, Moore LC. Direct visualization of renin-cell distribution in preglomerular vascular trees dissected from rat kidney. Am J Physiol 1993;265:F151-F156.
20. Casellas D, Bouriquet N, Herizi A. Bosentan prevents preglomerular alterations during angiotensin II hypertension. Hypertens 1997;30:1613-20.
21. Tharaux P-L, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule J-C. Vascular endothelin-1 expression and synthesis and effect on renal type 1 collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999;99:2185-91.
22. Li J-S, Deng LY, Grove K, Deschepper CF, Schiffrin EL. Comparison of effect of endothelin antagonism and angiotensin-converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with Nω-nitro-L arginine methyl ester. Correlation with topography of vascular endothelin-1 gene expression. Hypertens 1996;28:188-95.
23. Ono Y, Ono H, Frohlich ED. Hydrochlorothiazide exacerbates nitric oxide blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996;14:823-8.
24. Ono Y, Ono H, Matsuoka H, Fujimori T, Frohlich ED. Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertens 1999;34:609-16.
25. Nakamura Y, Ono H, Frohlich ED. Differential effects of T-and L-type calcium channel antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertens 1999;34:273-8.
26. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2000;57:651-61.
27. Bouriquet N, Casellas D. Chronic L-NAME hypertension in rats and autoregulation of juxtamedullary preglomerular vessels. Am J Physiol 1995;269:F190-F197.
28. Sventek P, Li J-S, Grove K, Deschepper CF, Schiffrin EL. Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. J Hypertens 1996;27:49-55.
29. Fujihara CK, Michellazzo SM, De Nucci G, Zatz R. Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition. Am J Physiol 1994;266:F697-F705.
30. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Lüscher TF. ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998;31[part 2]:499-504.
31. Kassab S, Miller MT, Novak J, Reckelhoff, Clower B, Granger JP. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens 1998;31[part 2]:397-402.
32. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 2000;57:1803-17.
33. Kashiwagi M, Shinozaki M, Hirakata H et al. Locally activated renin-angiotensin system associated with TGF-β1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000;11:616-24.
34. Muller DN, Mervaala EMA, Schmidt F et al. Effect of bosentan on NF-kB, inflammation and tissue factor in angiotensin II-induced end-organ damage. Hypertens 2000;36:282-90.
35. Yanagitani Y, Rakugi H, Okamura A et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertens 1999;33[part II]:335-9.